hVIVO plc
("hVIVO", the "Company" or
the "Group")
Director/PDMR
Dealings
hVIVO plc (AIM & Euronext:
HVO), a fast-growing specialist contract research
organisation (CRO) and world leader in testing infectious and
respiratory disease products using human challenge clinical trials,
has been notified that Cathal Friel, Chairman,
sold 21,159,177 ordinary shares in the Company earlier today at 29p
each ("the Sale") to satisfy institutional demand post the
Company's recent capital markets event.
The shares sold were held through
Raglan Road Capital Limited, a company owned and controlled by
Cathal Friel and his spouse, and Horizon Medical Technologies
Limited, an investment vehicle controlled by Cathal
Friel.
Cavendish and Peel Hunt both gave
their consent to the Sale.
Cathal Friel and the corporate
entities detailed above no longer hold any ordinary shares in the
Company.
For
further information please contact:
|
hVIVO plc
|
+44 (0) 20
7756 1300
|
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
|
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward
|
|
|
|
|
|
Peel Hunt LLP (Joint Broker)
|
+44 (0)20
7418 8900
|
|
James Steel, Dr Christopher Golden
|
|
|
|
|
|
Davy (Euronext Growth Adviser and Joint
Broker)
|
+353 (0) 1
679 6363
|
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
|
|
Walbrook PR (Financial PR & IR)
Stephanie Cuthbert / Phillip
Marriage /
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
|
| |
The information contained within this announcement is deemed
by the Company to constitute inside information as stipulated under
the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the
publication of this announcement via Regulatory Information Service
("RIS"), this inside information is now considered to be in the
public domain.
Notes to
Editors
About
hVIVO
hVIVO plc
(ticker: HVO) is a fast growing specialist contract research
organisation (CRO) and the world leader in testing infectious and
respiratory disease vaccines and therapeutics using human challenge
clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat
client base, which includes four of the top 10 largest global
biopharma companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which
includes virology, immunology biomarker and molecular testing. The
Group also offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London -
its new state-of-the-art facilities in Canary Wharf opened in 2024
and is the world's largest commercial human challenge trial unit,
with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers /
patients for its studies, the Group leverages its unique clinical
trial recruitment capability via its FluCamp volunteer screening
facilities in London and Manchester.
